Drug intelligence / Profile preview

IDC111

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IDC111 is a first-in-class monoclonal antibody currently under development by Prestige Biopharma. It is being investigated for the treatment of various solid tumors and is part of the company's innovative drug pipeline. As of early 2024, the candidate is in the lead identification stage of development. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is designed as a novel therapeutic agent to address unmet needs in oncology.

Beyond the preview

Go deeper on IDC111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC111.

Explore the full profile